首页> 外文期刊>The Breast : >NOEY2 mutations in primary breast cancers and breast hyperplasia.
【24h】

NOEY2 mutations in primary breast cancers and breast hyperplasia.

机译:原发性乳腺癌和乳腺增生中的NOEY2突变。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: The NOEY2 gene mutations and protein expression in human breast cancers, adjacent breast tissues and breast benign lesions were analysed to explore the potential correlation between the mutation spectrum and breast cancer development and progression. EXPERIMENTAL DESIGN: The promoter, exon and intron regions of NOEY2 gene were amplified by polymerase chain reaction (PCR) with DNA extracted from 50 human breast cancer and corresponding adjacent breast tissues as well as 50 breast benign lesions, respectively. The PCR products were then sequenced and analysed. The effect of mutations on the expression of NOEY2 protein by immunohistochemistry were proven as well. RESULTS: Twenty-one of 50 (42%) breast cancer mutations were identified in promoter (11 cases) and exon 2 (seven cases on untranslation region and three on coding region) and 17 of 50 (34%) adjacent breast tissues (all were atypical hyperplasia lesions) occurred mutations, including six promoter mutations and 11 exon 2 changes (10 cases on untranslation region and one on coding region). Interestingly, the mutations were identified in both breast cancers and the corresponding adjacent breast tissues collected from the same patient in seven of them. No mutation was identified in all benign breast tissues. Immunohistochemical analysis showed that two of 17 mutational adjacent breast tissue samples were NOEY2 immunoreaction negative, and in all 21 mutations of breast cancers five cases were of loss of NOEY2 expression. All mutations with immunoreaction negative factor were located at promoter and/or exon 2 coding region. NOEY2 gene mutations were not correlated with patient ages, histological types, tumour sizes, histological grades, clinical stages, axillary lymph node metastases or with the condition of hormone receptor (ER, PR) expression and HER2 amplification. CONCLUSIONS: The mutations of human NOEY2 were identified in human breast cancers and the corresponding adjacent breast tissues. The hot mutation spots were its promoter and exon 2 regions, and those occurring at the exon2 coding region and part of the promoter may alter the expression of NOEY2. The presence of NOEY2 mutations in human breast cancer and early-stage lesions indicates that NOEY2 mutations may be partly associated with breast tumourigenesis.
机译:目的:分析人乳腺癌,邻近乳腺组织和乳腺良性病变中NOEY2基因的突变和蛋白表达,以探讨突变谱与乳腺癌的发生发展之间的潜在关系。实验设计:通过聚合酶链反应(PCR),分别从50例人类乳腺癌和相应的邻近乳腺组织以及50例乳腺良性病变中提取DNA,扩增出NOEY2基因的启动子,外显子和内含子区域。然后对PCR产物进行测序和分析。还通过免疫组织化学证实了突变对NOEY2蛋白表达的影响。结果:在启动子(11例)和外显子2(未翻译区七例,编码区三例)和50例邻近乳腺组织中的17例(34%)中鉴定出二十五个(42%)乳腺癌突变(全部)是非典型增生性病变)发生的突变,包括6个启动子突变和11个外显子2变化(未翻译区10例,编码区1例)。有趣的是,在两个乳腺癌中以及从七个患者中从同一患者收集的相应的相邻乳房组织中都鉴定出了突变。在所有良性乳腺组织中均未发现突变。免疫组织化学分析显示,在17个突变的邻近乳腺组织样本中,有两个样本的NOEY2免疫反应阴性,在所有21个乳腺癌突变中,有5例的NOEY2表达缺失。具有免疫反应阴性因子的所有突变都位于启动子和/或外显子2编码区。 NOEY2基因突变与患者年龄,组织学类型,肿瘤大小,组织学等级,临床分期,腋窝淋巴结转移或激素受体(ER,PR)表达和HER2扩增情况无关。结论:在人乳腺癌和相应的邻近乳腺组织中鉴定出人NOEY2的突变。热点突变点是其启动子和外显子2区,发生在外显子2编码区和部分启动子的突变可能会改变NOEY2的表达。人乳腺癌和早期病变中NOEY2突变的存在表明NOEY2突变可能与乳腺肿瘤发生有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号